Similarly, JAK1 is activated by PRLR signaling in a subset of breast cancers (Neilson et al., 2007), while underexpression of JAK1 is needed for the invasion of immune response (Albacker et al., 2017; Chen et al., 2019). Here, JAK1 is linked to breast carcinoma.